Literature DB >> 26308348

Fibromyalgia and Obesity: The Association Between Body Mass Index and Disability, Depression, History of Abuse, Medications, and Comorbidities.

Carmen E Gota1, Sahar Kaouk, William S Wilke.   

Abstract

AIM: The aim of this study was to determine the frequency of increasing body mass index (BMI) in fibromyalgia (FM) and to understand the impact of increasing BMI on FM.
METHODS: Patients with FM were divided into 3 BMI classifications: normal weight, overweight, and obese. We then sought relationships of increasing BMI to core process FM variables and symptoms and disability, as well as medical comorbidities and demographic, socioeconomic, psychiatric, and treatment data.
RESULTS: Of 224 patients, 0.4% were underweight; 25.9%, normal weight; 29.9%, overweight; 43.8%, obese. We found no differences within groups with regard to age, gender, demographics, FM symptoms, FM impact questionnaire scores, and meeting the American College of Rheumatology 1990 criteria and FM survey criteria. Patients with FM who are obese, compared with normal-weight patients, have higher depression scores measured by Patient Health Questionnaire 9 (13.2 [6.6] vs 10.5 [6], P = 0.03), report increased disability by Health Assessment Questionnaire Disability Index scores (1.3 [0.6] vs 0.9 [0.6], P < 0.001), exercise less (8.4% vs 25.4%, P = 0.003), have more medical comorbidities (1.5 [1.3] vs 0.7 [0.9], P < 0.001), take more medications for FM (3.5 [2.2] vs 2.1 [1.8], P < 0.001), and report higher prevalence of abuse (48% vs 33.9%, P = 0.016) and sexual abuse (17.3% vs 6.8%, P = 0.01).
CONCLUSIONS: Compared with normal-weight patients, obese FM patients are more disabled, report more medical comorbidities, exercise less, have a higher incidence of abuse, report increased depressive symptoms, and take more medications for FM. Bivariate analysis showed association of increasing BMI with the Health Assessment Questionnaire Disability Index (not FM impact questionnaire) and depression. We confirm that the prevalence of overweight and obesity is high in FM and believe that physicians treating FM should be aware of our bivariate linear correlations and discuss weight loss with their FM patients. Even if increasing BMI is not intrinsic to FM, it contributes to poor mood and functional outcome and should be a treatment goal.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26308348     DOI: 10.1097/RHU.0000000000000278

Source DB:  PubMed          Journal:  J Clin Rheumatol        ISSN: 1076-1608            Impact factor:   3.517


  12 in total

1.  Obesity Moderates the Effects of Motivational Interviewing Treatment Outcomes in Fibromyalgia.

Authors:  Anthony S Kaleth; James E Slaven; Dennis C Ang
Journal:  Clin J Pain       Date:  2018-01       Impact factor: 3.442

2.  Adverse Childhood Experiences in a Post-bariatric Surgery Psychiatric Inpatient Sample.

Authors:  Kathryn Fink; Colin A Ross
Journal:  Obes Surg       Date:  2017-12       Impact factor: 4.129

3.  Association Between Low Vitamin D Levels and the Greater Impact of Fibromyalgia.

Authors:  Susyane Ribeiro Beserra; Fabiola Isabel Suano Souza; Roseli Oselka Saccardo Sarni; Myllena Maria de Morais Pereira
Journal:  J Clin Med Res       Date:  2020-06-25

4.  Increased risk of a suicide event in patients with primary fibromyalgia and in fibromyalgia patients with concomitant comorbidities: A nationwide population-based cohort study.

Authors:  Chen-Chia Lan; Chun-Hung Tseng; Jiunn-Horng Chen; Joung-Liang Lan; Yu-Chiao Wang; Gregory J Tsay; Chung-Yi Hsu
Journal:  Medicine (Baltimore)       Date:  2016-11       Impact factor: 1.889

Review 5.  Chronic Widespread Pain and Fibromyalgia Syndrome: Life-Course Risk Markers in Young People.

Authors:  Aidan C Tan; Tiina Jaaniste; David Champion
Journal:  Pain Res Manag       Date:  2019-05-05       Impact factor: 3.037

6.  Assessment of Cardiometabolic Risk Factors, Physical Activity Levels, and Quality of Life in Stratified Groups up to 10 Years after Bariatric Surgery.

Authors:  Larissa Monteiro Costa Pereira; Felipe J Aidar; Dihogo Gama de Matos; Jader Pereira de Farias Neto; Raphael Fabrício de Souza; Antônio Carlos Sobral Sousa; Rebeca Rocha de Almeida; Marco Antonio Prado Nunes; Albená Nunes-Silva; Walderi Monteiro da Silva Júnior
Journal:  Int J Environ Res Public Health       Date:  2019-06-04       Impact factor: 3.390

7.  Functional Status and Body Mass Index in Postmenopausal Women with Fibromyalgia: A Case-control Study.

Authors:  Laura Cerón Lorente; María Carmen García Ríos; Santiago Navarro Ledesma; Rosa María Tapia Haro; Antonio Casas Barragán; María Correa-Rodríguez; María Encarnación Aguilar Ferrándiz
Journal:  Int J Environ Res Public Health       Date:  2019-11-16       Impact factor: 3.390

8.  Common and Contrasting Characteristics of the Chronic Soft-Tissue Pain Conditions Fibromyalgia and Lipedema.

Authors:  Felix Angst; Thomas Benz; Susanne Lehmann; Peter Sandor; Stephan Wagner
Journal:  J Pain Res       Date:  2021-09-17       Impact factor: 3.133

9.  The relationship between body mass index and pain, disease activity, depression and anxiety in women with fibromyalgia.

Authors:  Burhan Fatih Koçyiğit; Ramazan Azim Okyay
Journal:  PeerJ       Date:  2018-05-28       Impact factor: 2.984

10.  The association between body mass index and fibromyalgia severity: data from a cross-sectional survey of 2339 patients.

Authors:  Fabiola Atzeni; Alessandra Alciati; Fausto Salaffi; Marco Di Carlo; Laura Bazzichi; Marcello Govoni; Giovanni Biasi; Manuela Di Franco; Flavio Mozzani; Elisa Gremese; Lorenzo Dagna; Alberto Batticciotto; Fabio Fischetti; Roberto Giacomelli; Serena Guiducci; Giuliana Guggino; Mario Bentivegna; Roberto Gerli; Carlo Salvarani; Gianluigi Bajocchi; Marco Ghini; Florenzo Iannone; Valeria Giorgi; Sonia Farah; Sara Bonazza; Stefano Barbagli; Chiara Gioia; Noemi Giuliana Marino; Annunziata Capacci; Giulio Cavalli; Antonella Cappelli; Francesco Carubbi; Francesca Nacci; Ilenia Riccucci; Maurizio Cutolo; Luigi Sinigaglia; Piercarlo Sarzi-Puttini
Journal:  Rheumatol Adv Pract       Date:  2021-03-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.